[Click eStock] "Celltrion to Continue Major Uptrend This Year"

[Asia Economy Reporter Jang Hyowon] Hanyang Securities forecasted on the 26th that Celltrion will continue its major upward trend this year as well.

Oh Byungyong, a researcher at Hanyang Securities, stated in a report on the same day, “Celltrion obtained European approval for 'Uplima,' a Humira biosimilar, in February this year. Humira was the largest-selling drug in 2019 with sales of approximately 24 trillion KRW,” and analyzed, “Although Uplima is not a first-mover product, its target market is about three times larger than the Remicade and Rituxan markets.”

He also said, “The launch of Uplima cannot be seen as a weaker event compared to the launches of Truxima and Remsima SC in 2017 and 2020,” and evaluated, “Currently, the situation is as positive for stock price increases as it was back then.”

Furthermore, he noted, “The domestically approved COVID-19 antibody treatment 'Rekkironaju' is also worth having high expectations for,” explaining, “Currently, only Lilly and Regeneron have approved COVID antibody treatments, so global supply is very insufficient.”

He continued, “According to Celltrion, Rekkironaju is expected to have a conservative global demand of over 1.5 million people, and assuming a conservative price of 1 million KRW per person, sales are projected to be around 1.5 trillion KRW.”

He added, “Celltrion’s stock price has experienced two major upward trends in the past, driven by momentum such as the European approval of Truxima in 2017 and the European approval of Remsima SC and U.S. approval of Truxima in 2020,” and predicted, “Celltrion will maintain high growth this year as well.”